Vitamin Shoppe (VSI) Misses Q4 EPS by 4c

Vitamin Shoppe (NYSE: VSI) reported Q4 EPS of $0.36, $0.04 worse than the analyst estimate of $0.40. Revenue for the quarter came in at $304.9 million versus the consensus estimate of $311.79 million.

Commenting on the quarter's results, Colin Watts, Chief Executive Officer of the Vitamin Shoppe stated, "Our top line growth is not yet where we want it to be as fourth quarter comparable sales were disappointing, but generally in line with our expectations. Although the external environment was more difficult than we planned coming into 2016, we made significant progress in rolling out initiatives tied to our reinvention strategy. While we are encouraged by the early results of these programs in 2016, we acknowledge that they will still take time to reach full scale. In addition to good progress on growth initiatives during the quarter, we were particularly pleased with accelerated progress in our cost reduction and margin enhancement initiatives, which are vital to building a stronger Return on Capital profile for our Company in 2017. We still have a ways to go to realize our full Reinvention vision, but we remain bullish about our long-term prospects for sustainable, profitable growth."

2017 GUIDANCE:

• Vitamin Shoppe sees FY2017 EPS of $1.95-$2.20, versus the consensus of $2.18.
• Total comparable sales growth flat to low single digit negative
• The opening of 15 new stores
• Remodel 10 to 15 stores into new format
• Capital expenditures of approximately $45 million

For earnings history and earnings-related data on Vitamin Shoppe (VSI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c